Reduction of radioactive seed embolization to the lung following prostate brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 5, 1998, Pages 1063-1067

  Tapen, Elizabeth M ^b   Blasko, John C ^a   Grimm, Peter D ^c   Ragde, Haakon ^d   Luse, Ray ^e   Clifford, Stephanie ^a   Sylvester, John ^c   Griffin, Thomas W ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Alta Bates Comprehensive Cancer Center   (United States)

^c SWEDISH MEDICAL CENTER   (United States)

^d PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^e Deaconess Medical Center Spokane   (United States)

Author keywords

Brachytherapy; Iodine 125; Palladium 103; Prostate; Pulmonary embolism

Indexed keywords

IODINE 125; PALLADIUM;

ARTICLE; BRACHYTHERAPY; CLINICAL TRIAL; DOSIMETRY; EMBOLISM; HUMAN; IMPLANTATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; THORAX RADIOGRAPHY; TREATMENT FAILURE;

BRACHYTHERAPY; FOREIGN-BODY MIGRATION; HUMANS; IODINE RADIOISOTOPES; MALE; PALLADIUM; PROSTATIC NEOPLASMS; PULMONARY EMBOLISM; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 0032437496     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00353-8     Document Type: Article

References (24)

1. Parker SL, Tong T, Bolden S.; et al. Cancer statistics, 1997. CA Cancer J Clin 1997; 47:5-27.
2. Middleton R.G., Thompson I.M., Austenfeld M.S., et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol. 154:1996;2144.
3. Blasko J.C., Ragde H., Luse R., et al. Should brachytherapy be considered a therapeutic option in localized prostate cancer? Urol Clin North Am. 23:1996;633-649.
4. Porter A.T., Blasko P.D., Reddy S.M., et al. Brachtherapy for prostate cancer. CA Cancer J Clin. 45:1995;165.
5. Nag S., Singhavajhala V., Mart'nez-Monge R. Pulmonary embolization of permanently implanted radioactive palladium-103 seeds for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 39:1997;667-670.
6. Grimm P.D., Blasko J., Ragde H., et al. Migration of iodine-125 and Palladium-103 seeds to the lung after transperineal brachytherapy for prostate cancer. Endocurie/Hypertherm Oncol. 9:1993;50.
7. Nag S., Scaperoth D., Badalament R., et al. Transperineal palladium-103 prostate brachytherapy: Analysis of morbidity and seed migration. Urology. 45:1995;87-92.
8. Gupta S., Nag S., Gupta J. Pulmonary embolisation of permanently implanted radioactive iodine-125 seeds. Endocurie/Hypertherm Oncol. 9:1993;27-31.
9. Steinfeld A.D., Donahue B.R., Plaine L. Pulmonary embolization of iodine-125 seeds following prostate implantation. Urology. 37:1991;149.
10. Moreno J.G., O'Hara S.M., Long J.P., et al. Transrectal ultrasound-guided biopsy causes hematogenous dissemination of prostate cells as determined by RT-PCR of PSA. Urology. 49:1997;515-520.
11. Sommerkamp H., Rupprecht M., Wannemacher M. Seed loss in interstitial radiotherapy of prostatic carcinoma with I-125. Int J Radiat Oncol Biol Phys. 14:1988;389-392.
12. Blasko J.C., Grimm P.D., Ragde H. Brachytherapy and organ preservation in the management of carcinoma of the prostate. Semin Radiat Oncol. 3:1993;240-247.
13. Blasko J.C., Ragde H., Schumacher D. Transperineal percutaneous Iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocurie/Hypertherm Oncol. 3:1987;131-139.
14. Grimm P.D., Blasko J.C., Ragde H. Ultrasound-guided tranperineal implantation of iodine-125 and palladium-103 for the treatment of early-stage prostate cancer. Urol Clin North Am. 2:1994;113-126.
15. Kumar P.P., Good R.R. Vicryl carrier for I-125 seeds: Percutaneous transperineal insertion. Radiology. 159:1986;276.
16. van't Riet A., te Loo H.J., Ypma A.F.G.V.M., et al. Ultrasonically guided transperineal seed implantation of the prostate: Modification of the technique and qualitative assessment of implants. Int J Radiat Oncol Biol Phys. 24:1986;555-558.
17. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 22:1995;209-234.
18. Kohn H.I., Fry R.J.M. Radiation carcinogenesis. N Engl J Med. 310:1984;504-511.
19. Wing S., Shy C.M., Wood J.L., et al. Mortality among workers at Oak Ridge National Laboratory. JAMA. 265:1991;1397.
20. Committee on the Biological Effects of Ionizing Radiation National Research Council. Health effects of exposure to low levels of ionizing radiation (BIER V). Washington, DC: National Academic Press; 1989.
21. NationalCouncil on Radiation Protection and Measurements. Influence of dose and its distribution in time on dose-response relationships for low LET radiation. Report No. 64. Washington, DC: NCRP; 1980.
22. Prasad S.C., Bassano D.A., Peng J.G. Lung density effect on I-125 dose distributions. Med Phys. 12:1985;99-100.
23. Dale R.G. Some theoretical derivations relating to the tissue dosimetry of brachytherapy nuclides, with particular reference to iodine-125. Med Phys. 10:1983;176-183.
24. Meigooni A.S., Nath R. Tissue inhomogeneity for brachytherapy sources in a heterogeneous phantom with cylindrical symmetry. Med Phys. 19:1992;401-407.